• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

D-VRd May Improve Minimal Residual Disease Responses in Multiple Myeloma

by | Dec 8, 2024 | Uncategorized

Source: CureToday articles For patients with transplant-ineligible or -deferred newly diagnosed multiple myeloma, the addition of Darzalex to VRd improved MRD responses as well as progression-free survival. Read More

High-fiber diet may slow progression of precursor conditions to multiple myeloma

by | Dec 7, 2024 | Uncategorized

SAN DIEGO — A high-fiber plant-based diet may delay progression of certain precursor conditions to multiple myeloma, according to study results presented at ASH Annual Meeting and Exposition.The intervention also improved biomarkers of the disease, results of the...

Blenrep Combo Accepted for FDA Review in R/R Multiple Myeloma

by | Dec 3, 2024 | Uncategorized

Source: CureToday articles The FDA has accepted a biologics license application for Blenrep plus bortezomib or pomalidomide for patients with relapsed or refractory multiple myeloma. Read More

Blenrep-Based Combo Provides Survival Benefit in Relapsed/Refractory Multiple Myeloma

by | Nov 18, 2024 | Uncategorized

Source: CureToday articles Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be presented at an upcoming conference. Read More

Triplet regimen extends OS in relapsed or refractory multiple myeloma

by | Nov 14, 2024 | Uncategorized

A triplet regimen extended OS compared with the current standard of care for patients with relapsed or refractory multiple myeloma, according to a topline data announcement.Patients with multiple myeloma often become refractory to first-line triplet or quadruplet...

QOL a Crucial Consideration During R/R Myeloma Treatment Decision-Making

by | Nov 12, 2024 | Uncategorized

Source: CureToday articles Patients with relapsed or refractory multiple myeloma should consider quality of life with survival when choosing the most suitable treatment option. Read More
« Older Entries
Next Entries »

Recent Content

  • Targeting proteostasis in multiple myeloma through inhibition of LTK
  • IsaKRD Induction Achieves 95% Response Rate in Multiple Myeloma
  • EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma
  • Patient-reported physical function has ‘real clinical value’ for treating multiple myeloma
  • Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma
  • The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
  • FDA Approves Linvoseltamab-Gcpt for Treatment of Relapsed or Refractory Multiple Myeloma
  • FDA Grants Accelerated Approval to Lynozyfic for Multiple Myeloma
  • FDA accelerates linvoseltamab-gcpt approval for multiple myeloma
  • Comprehensive machine learning analysis of PANoptosis signatures in multiple myeloma identifies prognostic and immunotherapy biomarkers
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT